Complement receptor 1 and 2 fusion proteins
AssigneesMUSC Foundation for Research Development, The Regents of the University of Colorado, a body corporate
InventorsStephen Tomlinson, V. Michael Holers
Life of this patent
Estimating the term…
Abstract
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
Claims13
A composition comprising a construct, wherein the construct is a fusion protein consisting of:
- (a) a complement receptor 2 (CR2) or a fragment thereof, wherein the fragment consists of at least the first two N-terminal short consensus repeat (SCR) domains of the CR2 protein;
- (b) a modulator of complement activity, wherein the modulator consists of one or more active sites of CR1;
- and
- (c) optionally, a linker linking (a) and (b).
Dependencies are inferred from the claim text.